title: Entecavir, FTC, L-FMAU, LdT and others.
abstract: To summarize, the future of chronic hepatitis B therapy seems to be the combination of different drugs. Ideally, the optimal drugs to combine would meet the following criteria: they should be orally applicable, they should have an excellent safety profile and the duration of therapy should limited. Currently, the drugs most likely to fulfill these criteria are the nucleoside analogs.
authors.affiliation: Liver Unit, Hospital General Universitari Vall d'Hebron, Paseo Valle de Hebron 119, Barcelona 08035, Spain. mbuti@hg.vhebron.es
authors.forename: Maria
authors.initials: M
authors.lastname: Buti
authors.forename: Rafael
authors.initials: R
authors.lastname: Esteban
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000068679:Emtricitabine; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D013936:Thymidine / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D003841:Deoxycytidine; D001086:Arabinofuranosyluracil; C413685:entecavir; D006147:Guanine; D000068679:Emtricitabine; C034935:clevudine; D013936:Thymidine